New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
07:53 EDTMYL, VRX, ENDP, PRGOPullback has created attractive pharma opportunities, says JPMorgan
JPMorgan believes nothing has fundamentally changed to warrant the recent pullback in the specialty pharmaceutical space and views the pullback as an attractive buying opportunity. JPMorgan named Endo Health (ENDP), Mylan (MYL), Perrigo (PRGO), and Valeant (VRX) as stocks on which it maintains Overweight ratings, citing their favorable positions given the wave of consolidation ongoing in the industry.
News For ENDP;MYL;PRGO;VRX From The Last 14 Days
Check below for free stories on ENDP;MYL;PRGO;VRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 21, 2014
07:15 EDTVRXValeant Allergan contacts Quebec, U.S. regulators regarding Allergan statements
Valeant (VRX) has contacted both the Autorite des marches financiers in Quebec and the SEC regarding Allergan (AGN) apparent attempt to "mislead investors and manipulate the market for Valeant common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting such information." The latest statements were made last Friday when Allergan asserted in an SEC filing that Bausch + Lomb's pharmaceutical sales were stagnant or declining. Valeant's decision to contact the authorities also reflects concerns raised by several Canadian Valeant shareholders about comments made about Valeant by Allergan's management during recent meetings with these investors in Canada.
07:09 EDTVRXValeant, Ackman go to SEC over Allergan claims, CNBC reports
Subscribe for More Information
06:34 EDTVRXCapital Research sells nearly all its Allergan stake, WSJ reports
Subscribe for More Information
July 18, 2014
16:47 EDTMYLMarket ends week higher as earnings, M&A offset geopolitical tensions
Subscribe for More Information
12:51 EDTVRX, MYLKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
11:27 EDTVRXSamlyn undecided on support for Valeant bid for Allergan, Dow says
Subscribe for More Information
09:35 EDTPRGOPerrigo would rather make acquisitions than be sold, dealReporter says
Subscribe for More Information
July 17, 2014
16:45 EDTVRXPershing Square looks to obtain consents for special meeting
Subscribe for More Information
11:07 EDTMYLAcorda sues Mylan over plans to duplicate Ampyra MS drug, Bloomberg says
08:08 EDTVRXValeant receives FDA clearance for Victus Femtosecond Laser Platform
Subscribe for More Information
07:18 EDTMYLMylan wins motion to enjoin GlaxoSmithKline from production of generic product
Subscribe for More Information
07:00 EDTVRXPaulson says Allergan could be wroth $220 per share, WSJ reports
Subscribe for More Information
July 16, 2014
17:46 EDTVRXAckman says he thinks Allergan-Valeant deal eventually gets done
Subscribe for More Information
17:42 EDTVRXPershing Square's Ackman says Allergan's attack on Valeant unprecedented
Subscribe for More Information
11:34 EDTPRGOPerrigo management to meet with Needham
Subscribe for More Information
10:36 EDTVRX, MYLTreasury calls on Congress to halt inversion deals
Subscribe for More Information
09:16 EDTVRXPershing Square sends letter to Allergan's board of directors
Pershing Square Capital Management announced it has sent a letter to Allergan's Board of Directors. Pershing Square last Friday filed definitive solicitation materials with the U.S. SEC to seek shareholder support for a special meeting of Allergan shareholders and is now actively soliciting shareholder support to call the meeting. At this special meeting, Allergan shareholders will be able to voice their opinions on a number of critical matters, including the proposed removal of six incumbent members of the Allergan board, the proposed appointment of an independent slate of directors and certain other proposed provisions to improve Allerganís corporate governance.
09:03 EDTMYLSanofi held talks on mature drugs with Abbott, Mylan, PE firms, Reuters says
Sanofi (SNY) has shopped an $8.5B portfolio of mature drugs to Abbott (ABT), Mylan (MYL) and private equity firms, according to Reuters, citing an internal company document circulated by the CGT union. Sanofi is considering whether to sell, carve out or create a joint venture for the portfolio of about 200 drugs, but a Sanofi spokesman said no decision has yet been made, the report noted. Reference Link
08:16 EDTVRX, MYLLew's letter could bring 'chilly' tax inversion environment, says BMO Capital
Subscribe for More Information
07:59 EDTPRGO, MYL, VRXTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use